Harmonization of Activity Determination Requirements for Recombinant Blood Clotting Factor rFVIIa


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Тек жазылушылар үшін

Аннотация

The interchangeability of coagulation methods for determining the activity of recombinant blood clotting factor rFVIIa was assessed. Single-factor analysis of variance (ANOVA) and comparison of the metrological characteristics of the methods led to the conclusion that results obtained by reproducing the methods of the European Pharmacopoeia and Generium were comparable and interchangeable. One method could be used to confirm that a drug conformed to regulations established using another method. The Generium method was chosen for introduction into national pharmacopoeial practice because it was more economical.

Авторлар туралы

O. Ustinnikova

Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Public Health of the Russian Federation; Generium Inc.

Хат алмасуға жауапты Автор.
Email: Ustinnikova@expmed.ru
Ресей, 8/2 Petrovskii Blvd., Moscow, 127051; Moscow

E. Novikova

Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Public Health of the Russian Federation

Email: Ustinnikova@expmed.ru
Ресей, 8/2 Petrovskii Blvd., Moscow, 127051

O. Runova

Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Public Health of the Russian Federation

Email: Ustinnikova@expmed.ru
Ресей, 8/2 Petrovskii Blvd., Moscow, 127051

D. Shvedov

Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Public Health of the Russian Federation

Email: Ustinnikova@expmed.ru
Ресей, 8/2 Petrovskii Blvd., Moscow, 127051

M. Zhilyaeva

Generium International Biotechnology Center

Email: Ustinnikova@expmed.ru
Ресей, Moscow, 123317

D. Kudlai

Generium Inc.

Email: Ustinnikova@expmed.ru
Ресей, Moscow

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML

© Springer Science+Business Media, LLC, 2017